Elanco Animal Health Files 8-K
Ticker: ELAN · Form: 8-K · Filed: Oct 16, 2024 · CIK: 1739104
| Field | Detail |
|---|---|
| Company | Elanco Animal Health Inc (ELAN) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, regulation-fd
Related Tickers: ELAN
TL;DR
Elanco filed a standard 8-K on 10/16/24, no major news.
AI Summary
Elanco Animal Health Incorporated filed an 8-K on October 16, 2024, to report information under Regulation FD. The filing does not contain specific financial figures or material events beyond the standard reporting requirement for the date.
Why It Matters
This filing indicates Elanco Animal Health is adhering to its regulatory disclosure obligations with the SEC.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain any new material information that would impact risk.
Key Players & Entities
- Elanco Animal Health Incorporated (company) — Registrant
- October 16, 2024 (date) — Date of Report
FAQ
What is the purpose of this 8-K filing?
This 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically for a Regulation FD Disclosure.
What is the exact name of the registrant?
The exact name of the registrant is Elanco Animal Health Incorporated.
In which state is Elanco Animal Health Incorporated incorporated?
Elanco Animal Health Incorporated is incorporated in Indiana.
What is the principal executive office address of Elanco Animal Health?
The address of the principal executive offices is 2500 Innovation Way, Greenfield, Indiana 46140.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (877) 352-6261.
Filing Stats: 601 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2024-10-16 06:30:13
Filing Documents
- tm2425466d1_8k.htm (8-K) — 26KB
- 0001104659-24-108914.txt ( ) — 233KB
- elan-20241016.xsd (EX-101.SCH) — 3KB
- elan-20241016_def.xml (EX-101.DEF) — 26KB
- elan-20241016_lab.xml (EX-101.LAB) — 35KB
- elan-20241016_pre.xml (EX-101.PRE) — 25KB
- tm2425466d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On October 15, 2024, representatives of Elanco Animal Health Incorporated (the "Company") presented the abstract titled "Serologic response to core booster vaccinations in dogs treated with a novel JAK inhibitor" at the International Society for Companion Animal Infectious Diseases (ISCAID) symposium. The Zenrelia (ilunocitinib tablets) study summarized in the abstract was conducted by the Company with sixty-eight approximately 10-month-old Beagle dogs previously vaccinated more than seven months prior to receiving a booster vaccination. The dogs were randomly assigned to three treatment groups stratified by sex and pre-study titer levels: sham dosed (control group) and ilunocitinib at 1X or 3X the label dose. The study concluded that when dogs were administered ilunocitinib for 56 days at 1X or 3X the labeled dose, the number of dogs with protective titers on days 43 and 56 following administration of canine core booster vaccinations, including rabies, were similar among all treated and control groups. No serious adverse events were observed. A copy of the abstract has been posted on the Company's Investors Relations website under the "Zenrelia Approval Call" event. Additionally, the Company has received approval for Zenrelia in Canada. Further information is available via the Health Canada Drug Product Database website. The information in this Item 7.01 is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elanco Animal Health Incorporated Date: October 16, 2024 By: /s/ Todd Young Name: Todd Young Title: Executive Vice President and Chief Financial Officer